Effective GDNF brain delivery using microspheres-A promising strategy for Parkinson's disease

Journal of Controlled Release

Volumn 135, Issue 2, 2009, Pages 119-126

  Garbayo, E ^a   Montero Menei, C N ^b   Ansorena, E ^a   Lanciego, J L ^c   Aymerich, M S ^c   Blanco Prieto, M J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITÉ D'ANGERS   (France)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

GDNF; Parkinson's disease; PLGA microparticles; Serum IgG antibodies against GDNF; TROMS

Indexed keywords

GDNF; PARKINSON'S DISEASE; PLGA MICROPARTICLES; SERUM IGG ANTIBODIES AGAINST GDNF; TROMS;

ANIMALS; ANTIBODIES; BODY FLUIDS; CELL CULTURE; MICROSPHERES;

DISEASES;

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCOSYLATED PROTEIN; IMMUNOGLOBULIN G ANTIBODY; MICROSPHERE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MANUFACTURE; DRUG RELEASE; DRUG SAFETY; DRUG SYNTHESIS; FEMALE; NONHUMAN; PARKINSON DISEASE; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; RAT; TOTAL RECIRCULATION ONE MACHINE SYSTEM;

ANIMALS; BRAIN; CELL DIFFERENTIATION; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLYCOSYLATION; IMMUNOHISTOCHEMISTRY; KINETICS; LACTIC ACID; MICROSPHERES; MODELS, NEUROLOGICAL; PARKINSON DISEASE; PARTICLE SIZE; PC12 CELLS; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 62849092122     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.12.010     Document Type: Article

References (28)

1. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 5111 (1993) 1130-1132
2. Grondin R., and Gash D.M. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. J. Neurol. 245 11 Suppl 3 (1998) P35-P42
3. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., and Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9 5 (2003) 589-595
4. Patel N.K., Bunnage M., Plaha P., Svendsen C.N., Heywood P., and Gill S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 57 2 (2005) 298-302
5. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., and Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 102 2 (2005) 216-222
6. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., and Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59 3 (2006) 459-466
7. Hutchinson M., Gurney S., and Newson R. GDNF in Parkinson disease: an object lesson in the tyranny of type II. J. Neurosci. Methods 163 2 (2007) 190-192
8. Behrstock S., Ebert A., McHugh J., Vosberg S., Moore J., Schneider B., Capowski E., Hei D., Kordower J., Aebischer P., and Svendsen C.N. Human neural progenitors deliver glial cell line-derived neurotrophic factor to Parkinsonian rodents and aged primates. Gene Ther. 13 5 (2006) 379-388
9. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., and Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 5492 (2000) 767-773
10. Palfi S., Leventhal L., Chu Y., Ma S.Y., Emborg M., Bakay R., Deglon N., Hantraye P., Aebischer P., and Kordower J.H. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J. Neurosci. 22 12 (2002) 4942-4954
11. Eslamboli A., Georgievska B., Ridley R.M., Baker H.F., Muzyczka N., Burger C., Mandel R.J., Annett L., and Kirik D. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J. Neurosci. 25 4 (2005) 769-777
12. Grandoso L., Ponce S., Manuel I., Arrue A., Ruiz-Ortega J.A., Ulibarri I., Orive G., Hernandez R.M., Rodriguez A., Rodriguez-Puertas R., Zumarraga M., Linazasoro G., Pedraz J.L., and Ugedo L. Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats. Int. J. Pharm. 343 1-2 (2007) 69-78
13. Blanco-Prieto M.J., Durieux C., Dauge V., Fattal E., Couvreur P., and Roques B.P. Slow delivery of the selective cholecystokinin agonist pBC 264 into the rat nucleus accumbens using microspheres. J. Neurochem. 67 6 (1996) 2417-2424
14. Emerich D.F., Tracy M.A., Ward K.L., Figueiredo M., Qian R., Henschel C., and Bartus R.T. Biocompatibility of poly (dl-lactide-co-glycolide) microspheres implanted into the brain. Cell Transplant 8 1 (1999) 47-58
15. Veziers J., Lesourd M., Jollivet C., Montero-Menei C., Benoit J.P., and Menei P. Analysis of brain biocompatibility of drug-releasing biodegradable microspheres by scanning and transmission electron microscopy. J. Neurosurg. 95 3 (2001) 489-494
16. Fournier E., Passirani C., Montero-Menei C.N., and Benoit J.P. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 24 19 (2003) 3311-3331
17. Bilati U., Allemann E., and Doelker E. Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur. J. Pharm. Biopharm. 59 3 (2005) 375-388
18. del Barrio G., Novo F.J., and Irache J.M. Loading of plasmid DNA into PLGA microparticles using TROMS (Total Recirculation One-Machine System): evaluation of its integrity and controlled release properties. J. Control. Release 86 1 (2003) 123-130
19. Garbayo E., Ansorena E., Lanciego J.L., Aymerich M.S., and Blanco-Prieto M.J. Sustained release of bioactive glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres. Eur. J. Pham. Biophar. 69 3 (2008) 844-851
20. Garbayo E., Ansorena E., Lanciego J.L., Aymerich M.S., and Blanco-Prieto M.J. Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor. Int. J. Pharm. 344 1-2 (2007) 9-15
21. Cao X., and Schoichet M.S. Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders. Biomaterials 20 4 (1999) 329-339
22. Kirik D., Rosenblad C., and Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 2 (1998) 259-277
23. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1996), Academic Press, Orlando
24. Menei P., Pean J.M., Nerriere-Daguin V., Jollivet C., Brachet P., and Benoit J.P. Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage. Exp. Neurol. 161 1 (2000) 259-272
25. Hong M., Mukhida K., and Mendez I. GDNF therapy for Parkinson's disease. Expert. Rev. Neurother. 8 7 (2008) 1125-1139
26. Jollivet C., Aubert-Pouessel A., Clavreul A., Venier-Julienne M.C., Remy S., Montero-Menei C.N., Benoit J.P., and Menei P. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. Biomaterials 25 5 (2004) 933-942
27. Jollivet C., Aubert-Pouessel A., Clavreul A., Venier-Julienne M.C., Montero-Menei C.N., Benoit J.P., and Menei P. Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease. Neurosci. Lett. 356 3 (2004) 207-210
28. Sherer T.B., Fiske B.K., Svendsen C.N., Lang A.E., and Langston J.W. Crossroads in GDNF therapy for Parkinson's disease. Mov. Disord. 21 2 (2006) 136-141